Denali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary

Denali Therapeutics

06/08/2026 22:01

Denali Therapeutics Inc. DNLI.OQ reported a quarterly adjusted loss of 68 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -72 cents.  The mean expectation of twenty analysts for the quarter was for a loss of 66 cents per share. Wall Street expected results to range from -89 cents to 1 cents per share.
Revenue was $3.60 million​; analysts expected $14.61 million. 
Denali Therapeutics Inc.'s reported EPS for the quarter was a loss of 68 cents​.
The company reported a quarterly loss of $127.55 million.
Denali Therapeutics Inc. shares had fallen by 5.1% this quarter and gained 47.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 11.6% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Denali Therapeutics Inc. is $35.00, about 30.2% above its last closing price of $24.42
This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.66
-0.68
Missed
Mar. 31 2026 
-0.73
-0.69
Beat
Dec. 31 2025 
-0.74
-0.73
Beat
Sep. 30 2025 
-0.75
-0.74
Beat